
Europe Gene Expression Market Report and Forecast 2024-2032
Description
Europe Gene Expression Market Report and Forecast 2024-2032
Europe Gene Expression Market Report and Forecast 2024-2032
Europe Gene Expression Market Outlook
The global gene expression market size was valued at USD 13.3 billion in 2023, with Europe holding a significant market share. It is driven by the increasing research activities and regulatory approvals. The market is expected to grow at a CAGR of 9.10% during the forecast period of 2024-2032, with the values likely to reach USD 32.4 billion by 2032.
Key Takeaways
- The market is projected to witness an upward trajectory owing to the increasing research and investment activities in new drug discoveries for chronic diseases such as cancer, among others.
- United Kingdom is cementing its position as the leading destination of clinical trials in cell and gene therapy in Europe and is expected to lead the Europe gene expression market share in coming years.
- The market is impacted by increasing approvals from regulatory authorities. In February 2024, Vertex Pharmaceuticals and CRISPR Therapeutics received European Commission’s marketing approval for Casgevy (exagamglogene autotemcel).
Gene expression enables any specific part of DNA to contribute to the basic functionality of different cells in the human body including nerve cells and neurons in the brain. It is a fundamental aspect of gene therapies as it includes procedures like altering or silencing genes within a patient's cells to treat or prevent disease.
In February 2024, Vertex Pharmaceuticals and CRISPR Therapeutics received regulatory approval for Casgevy (exagamglogene autotemcel) after receiving conditional marketing authorisation for gene therapy from the European Commission. The CRISPR treatment is the first gene therapy approved in Europe for sickle cell disease and transfusion-dependent beta-thalassemia (TDT). The approval of Casgevy for the treatment of sickle cell disease and transfusion-dependent beta-thalassemia (TDT) represents a significant development, propelling the Europe gene expression market growth.
United Kingdom’s market share is poised to witness a notable upswing in the forecast period. The growth can be attributed to its increasing expenditure on conducting more clinical trials in cell and gene therapy. United Kingdom is the leading destination for cell and gene therapy clinical trials, with 84 drugs in clinical development as of October 2023, followed by France (45), Spain (44), and Germany (40). Europe gene expression market demand is further fuelled by abundance of innovations in bioscience and healthcare. Despite experiencing significant lows in the past, market players have significantly gained hefty investments as venture capital (VC) funding. Notably, half of the VC funding has been secured by European cell and gene therapy companies in 2023 contributing to the expansion of market share.
With increasing preference for personalised medicine, gene expression is finding its application in treatment of several chronic diseases, including cancer. This is one of the major Europe gene expression market trends. In January 2024, researchers from the Wellcome Sanger Institute conducted an analysis of 370 candidate priority drugs across various cancer types including lung, ovarian and breast candidates. With gene expression analysis, the comprehension of the functional and genomic information of cancer cells becomes feasible contributing to the development of more effective cancer treatments. Such advancements in cancer research and therapy development with gene expression are likely to significantly impact the gene expression market in Europe and globally.
Europe Gene Expression Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Process
- Sample Collection
- Purification
- cDNA Synthesis & Conversion
- PCR Analysis
- Data Analysis & Interpretation
- Clinical Diagnostics
- Drug Discovery & Development
- Research Activities
- Other Applications
- RNA Expression
- Promoter Analysis
- Protein Expression & Posttranslational Modification Analysis
- Consumables
- Instruments
- Services
- Pharmaceutical and biotechnology companies
- Diagnostic laboratories
- Academic research centers
- United Kingdom
- Germany
- France
- Italy
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- F. Hoffmann-La Roche Ltd
- QIAGEN
- Oxford Gene Technology (OGT) Group
- Eurofins Scientific
- LGC Limited
- Promega Corporation
- Takara Bio Inc.
- PacBio
- Smith & Nephew plc
- Abbott
FAQs
- What is the Europe gene expression market forecast outlook for 2024-2032?
- What are the major factors aiding the Europe gene expression market demand?
- What are the major Europe gene expression market trends?
- What are the market segmentations based on the process?
- Where does gene expression find its application?
- What techniques are used in the gene expression market?
- What are the products in the market?
- Who are the end users in the market?
- What is the market segmentation by countries?
- Who are the key players involved in the European gene expression market?
Meta description
Europe gene expression market size is estimated to grow, driven by the expansion in the global market, was valued at USD 13.3 billion in 2023 and it is anticipated to grow at a CAGR of 10.42% during the forecast period of 2024-2032.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
Table of Contents
140 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Europe Gene Expression Market Overview
- 3.1 Europe Gene Expression Market Historical Value (2017-2023)
- 3.2 Europe Gene Expression Market Forecast Value (2024-2032)
- 4 Europe Gene Expression Market Landscape*
- 4.1 Europe Gene Expression: Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Europe Gene Expression: Product Landscape
- 4.2.1 Analysis by Process
- 4.2.2 Analysis by Application
- 5 Europe Gene Expression Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.2.1 Strengths
- 5.2.2 Weaknesses
- 5.2.3 Opportunities
- 5.2.4 Threats
- 5.3 Porter’s Five Forces Model
- 5.3.1 Bargaining Power of Suppliers
- 5.3.2 Bargaining Power of Buyers
- 5.3.3 Threat of New Entrants
- 5.3.4 Threat of Substitutes
- 5.3.5 Degree of Rivalry
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Europe Gene Expression Market Segmentation (2017-2032)
- 6.1 Europe Gene Expression Market (2017-2032) by Process
- 6.1.1 Market Overview
- 6.1.2 Sample Collection
- 6.1.3 Purification
- 6.1.4 cDNA Synthesis & Conversion
- 6.1.5 PCR Analysis
- 6.1.6 Data Analysis & Interpretation
- 6.2 Europe Gene Expression Market (2017-2032) by Application
- 6.2.1 Market Overview
- 6.2.2 Clinical Diagnostics
- 6.2.3 Drug Discovery & Development
- 6.2.4 Research Activities
- 6.2.5 Other Applications
- 6.3 Europe Gene Expression Market (2017-2032) by Technique
- 6.3.1 Market Overview
- 6.3.2 RNA Expression
- 6.3.3 Promoter Analysis
- 6.3.4 Protein Expression & Posttranslational Modification Analysis
- 6.4 Europe Gene Expression Market (2017-2032) by Product
- 6.4.1 Market Overview
- 6.4.2 Consumables
- 6.4.3 Instruments
- 6.4.4 Services
- 6.5 Europe Gene Expression Market (2017-2032) by End User
- 6.5.1 Market Overview
- 6.5.2 Pharmaceutical and biotechnology companies
- 6.5.3 Diagnostic laboratories
- 6.5.4 Academic research centers
- 6.6 Europe Gene Expression Market (2017-2032) by Country
- 6.6.1 Market Overview
- 6.6.2 United Kingdom
- 6.6.3 Germany
- 6.6.4 France
- 6.6.5 Italy
- 7 United Kingdom Gene Expression Market (2017-2032)
- 7.1 United Kingdom Gene Expression Market (2017-2032) by Process
- 7.1.1 Market Overview
- 7.1.2 Sample Collection
- 7.1.3 Purification
- 7.1.4 cDNA synthesis & conversion
- 7.1.5 PCR Analysis
- 7.1.6 Data analysis & interpretation
- 7.2 United Kingdom Gene Expression Market (2017-2032) by Application
- 7.2.1 Market Overview
- 7.2.2 Clinical Diagnostics
- 7.2.3 Drug Discovery & Development
- 7.2.4 Research Activities
- 7.2.5 Other Applications
- 7.3 United Kingdom Gene Expression Market (2017-2032) by Technique
- 7.3.1 Market Overview
- 7.3.2 RNA Expression
- 7.3.3 Promoter Analysis
- 7.3.4 Protein Expression & Posttranslational Modification Analysis
- 7.4 United Kingdom Gene Expression Market (2017-2032) by Product
- 7.4.1 Market Overview
- 7.4.2 Consumables
- 7.4.3 Instruments
- 7.4.4 Services
- 7.5 United Kingdom Gene Expression Market (2017-2032) by End User
- 7.5.1 Market Overview
- 7.5.2 Pharmaceutical and biotechnology companies
- 7.5.3 Diagnostic laboratories
- 7.5.4 Academic research centers
- 8 Germany Gene Expression Market (2017-2032)
- 8.1 Germany Gene Expression Market (2017-2032) by Process
- 8.1.1 Market Overview
- 8.1.2 Sample Collection
- 8.1.3 Purification
- 8.1.4 cDNA synthesis & conversion
- 8.1.5 PCR Analysis
- 8.1.6 Data analysis & interpretation
- 8.2 Germany Gene Expression Market (2017-2032) by Application
- 8.2.1 Market Overview
- 8.2.2 Clinical Diagnostics
- 8.2.3 Drug Discovery & Development
- 8.2.4 Research Activities
- 8.2.5 Other Applications
- 8.3 Germany Gene Expression Market (2017-2032) by Technique
- 8.3.1 Market Overview
- 8.3.2 RNA Expression
- 8.3.3 Promoter Analysis
- 8.3.4 Protein Expression & Posttranslational Modification Analysis
- 8.4 Germany Gene Expression Market (2017-2032) by Product
- 8.4.1 Market Overview
- 8.4.2 Consumables
- 8.4.3 Instruments
- 8.4.4 Services
- 8.5 Germany Gene Expression Market (2017-2032) by End User
- 8.5.1 Market Overview
- 8.5.2 Pharmaceutical and biotechnology companies
- 8.5.3 Diagnostic laboratories
- 8.5.4 Academic research centers
- 9 France Gene Expression Market (2017-2032)
- 9.1 France Gene Expression Market (2017-2032) by Process
- 9.1.1 Market Overview
- 9.1.2 Sample Collection
- 9.1.3 Purification
- 9.1.4 cDNA synthesis & conversion
- 9.1.5 PCR Analysis
- 9.1.6 Data analysis & interpretation
- 9.2 France Gene Expression Market (2017-2032) by Application
- 9.2.1 Market Overview
- 9.2.2 Clinical Diagnostics
- 9.2.3 Drug Discovery & Development
- 9.2.4 Research Activities
- 9.2.5 Other Applications
- 9.3 France Gene Expression Market (2017-2032) by Technique
- 9.3.1 Market Overview
- 9.3.2 RNA Expression
- 9.3.3 Promoter Analysis
- 9.3.4 Protein Expression & Posttranslational Modification Analysis
- 9.4 France Gene Expression Market (2017-2032) by Product
- 9.4.1 Market Overview
- 9.4.2 Consumables
- 9.4.3 Instruments
- 9.4.4 Services
- 9.5 France Gene Expression Market (2017-2032) by End User
- 9.5.1 Market Overview
- 9.5.2 Pharmaceutical and biotechnology companies
- 9.5.3 Diagnostic laboratories
- 9.5.4 Academic research centers
- 10 Italy Gene Expression Market (2017-2032)
- 10.1 Italy Gene Expression Market (2017-2032) by Process
- 10.1.1 Market Overview
- 10.1.2 Sample Collection
- 10.1.3 Purification
- 10.1.4 cDNA synthesis & conversion
- 10.1.5 PCR Analysis
- 10.1.6 Data analysis & interpretation
- 10.2 Italy Gene Expression Market (2017-2032) by Application
- 10.2.1 Market Overview
- 10.2.2 Clinical Diagnostics
- 10.2.3 Drug Discovery & Development
- 10.2.4 Research Activities
- 10.2.5 Other Applications
- 10.3 Italy Gene Expression Market (2017-2032) by Technique
- 10.3.1 Market Overview
- 10.3.2 RNA Expression
- 10.3.3 Promoter Analysis
- 10.3.4 Protein Expression & Posttranslational Modification Analysis
- 10.4 Italy Gene Expression Market (2017-2032) by Product
- 10.4.1 Market Overview
- 10.4.2 Consumables
- 10.4.3 Instruments
- 10.4.4 Services
- 10.5 Italy Gene Expression Market (2017-2032) by End User
- 10.5.1 Market Overview
- 10.5.2 Pharmaceutical and biotechnology companies
- 10.5.3 Diagnostic laboratories
- 10.5.4 Academic research centers
- 11 Regulatory Framework
- 12 Patent Analysis
- 12.1 Analysis by Type of Patent
- 12.2 Analysis by Publication Year
- 12.3 Analysis by Issuing Authority
- 12.4 Analysis by Patent Age
- 12.5 Analysis by CPC Analysis
- 12.6 Analysis by Patent Valuation
- 12.7 Analysis by Key Players
- 13 Grants Analysis
- 13.1 Analysis by Year
- 13.2 Analysis by Amount Awarded
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Grant Application
- 13.5 Analysis by Funding Institute
- 13.6 Analysis by Departments
- 13.7 Analysis by Recipient Organization
- 14 Funding and Investment Analysis
- 14.1 Analysis by Funding Instances
- 14.2 Analysis by Type of Funding
- 14.3 Analysis by Funding Amount
- 14.4 Analysis by Leading Players
- 14.5 Analysis by Leading Investors
- 14.6 Analysis by Geography
- 15 Partnership and Collaborations Analysis
- 15.1 Analysis by Partnership Instances
- 15.2 Analysis by Type of Partnership
- 15.3 Analysis by Leading Players
- 15.4 Analysis by Geography
- 16 Supplier Landscape
- 16.1 Market Share by Top 5 Companies
- 16.2 F. Hoffmann-La Roche Ltd
- 16.2.1 Financial Analysis
- 16.2.2 Product Portfolio
- 16.2.3 Demographic Reach and Achievements
- 16.2.4 Mergers and Acquisitions
- 16.2.5 Certifications
- 16.3 QIAGEN
- 16.3.1 Financial Analysis
- 16.3.2 Product Portfolio
- 16.3.3 Demographic Reach and Achievements
- 16.3.4 Mergers and Acquisitions
- 16.3.5 Certifications
- 16.4 Oxford Gene Technology (OGT) Group
- 16.4.1 Financial Analysis
- 16.4.2 Product Portfolio
- 16.4.3 Demographic Reach and Achievements
- 16.4.4 Mergers and Acquisitions
- 16.4.5 Certifications
- 16.5 Eurofins Scientific
- 16.5.1 Financial Analysis
- 16.5.2 Product Portfolio
- 16.5.3 Demographic Reach and Achievements
- 16.5.4 Mergers and Acquisitions
- 16.5.5 Certifications
- 16.6 LGC Limited
- 16.6.1 Financial Analysis
- 16.6.2 Product Portfolio
- 16.6.3 Demographic Reach and Achievements
- 16.6.4 Mergers and Acquisitions
- 16.6.5 Certifications
- 16.7 Promega Corporation
- 16.7.1 Financial Analysis
- 16.7.2 Product Portfolio
- 16.7.3 Demographic Reach and Achievements
- 16.7.4 Mergers and Acquisitions
- 16.7.5 Certifications
- 16.8 Takara Bio Inc.
- 16.8.1 Financial Analysis
- 16.8.2 Product Portfolio
- 16.8.3 Demographic Reach and Achievements
- 16.8.4 Mergers and Acquisitions
- 16.8.5 Certifications
- 16.9 PacBio
- 16.9.1 Financial Analysis
- 16.9.2 Product Portfolio
- 16.9.3 Demographic Reach and Achievements
- 16.9.4 Mergers and Acquisitions
- 16.9.5 Certifications
- 16.10 Smith & Nephew plc.
- 16.10.1 Financial Analysis
- 16.10.2 Product Portfolio
- 16.10.3 Demographic
- 16.10.4 Mergers and Acquisitions
- 16.10.5 Certifications
- 16.11 Abbott
- 16.11.1 Financial Analysis
- 16.11.2 Product Portfolio
- 16.11.3 Demographic Reach and Achievements
- 16.11.4 Mergers and Acquisitions
- 16.11.5 Certifications
- 17 Europe Gene Expression Market – Distribution Model (Additional Insight)
- 17.1 Overview
- 17.2 Potential Distributors
- 17.3 Key Parameters for Distribution Partner Assessment
- 18 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 19 Company Competitiveness Analysis (Additional Insight)
- 19.1 Very Small Companies
- 19.2 Small Companies
- 19.3 Mid-Sized Companies
- 19.4 Large Companies
- 19.5 Very Large Companies
- 20 Payment Methods (Additional Insight)
- 20.1 Government Funded
- 20.2 Private Insurance
- 20.3 Out-of-Pocket
- *Additional insights provided are customisable as per client requirements.
- * The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.